

2024

EDITORIAL CALENDAR

	FEBRUARY	MARCH	APRIL	MAY
 <p>SPOTLIGHT</p>	<p>Assessing the evolving I-O landscape: key challenges and opportunities for 2024</p>	<p>Combination therapy development</p>		
 <p>CHANNEL FOCUS Tools & Technologies</p>		<p>Practical considerations for cutting edge tech</p>		
JUNE	JULY	AUGUST	SEPTEMBER	OCTOBER
	<p>Clinical development strategy</p>		<p>Improving patient selection and stratification</p>	<p>Translational insights: bridging the gap from preclinical R&D to the clinic</p>
	<p>Turning data into knowledge</p>			
NOVEMBER	DECEMBER	<p>Tools & Technologies channel</p> <ul style="list-style-type: none"> ▶ Channels allow us to zoom right in on specific aspects of topic areas that are of special interest to BioInsights members. ▶ The Tools & Technologies channel will feature three editions in 2024, covering topics such as AI, multiomics and <i>in vivo</i> tools. 		<p>Each spotlight will comprise:</p> <ul style="list-style-type: none"> ▶ Peer-reviewed Reviews and Expert Insight articles written by leading experts in the field ▶ Webinars, featuring industry speakers and sponsors discussing key topics specific to the Spotlight ▶ Podcast, written and video interviews with key opinion leaders ▶ On demand roundtable discussions
<p>Addressing ongoing safety and toxicity issues</p>	<p>Tools and trends of tomorrow</p>	<p>Immuno-Oncology Insights' spotlights provide you with fantastic opportunities to:</p> <ul style="list-style-type: none"> ▶ Educate your target market about your company's expertise, capabilities and experience ▶ Share your latest data with organizations looking for partners and service providers in your field ▶ Profile your executives and scientists as thought-leaders and KOLs ▶ Generate qualified leads from across the global sector ▶ Increase awareness of your company's role in immuno-oncology R&D 		
	<p>Preclinical tools update</p>			

EDITORIAL CALENDAR



Spotlight details

FEBRUARY

Assessing the evolving I-O landscape: key challenges and opportunities for 2024

- ▶ Progress being made in solid tumors
- ▶ Are cancer vaccines back from the dead?
- ▶ What's next for checkpoints?
 - ▶ What will the development of biosimilars mean for the field?
- ▶ Investor, financial, and market access trends

MARCH

Combination therapy development

- ▶ Are multimodality approaches the future of the field?
- ▶ With combination trials proving complex and expensive, how can resources best be deployed/ trial design be optimized?
- ▶ Combinations in solid tumors—opportunities and challenges
- ▶ Safety considerations: will synergistic effect also result in synergistic toxicity?

JULY

Clinical development strategy

- ▶ Clinical trial design innovation
- ▶ Dose selection and optimization
- ▶ Assessing the shifting regulatory landscape
- ▶ How can the I-O community work to increase global patient access?
- ▶ Increasing diversity and including the patient voice in clinical trial strategy and planning

SEPTEMBER

Improving patient selection and stratification

- ▶ Monitoring response and predicting outcome—how can different streams of data (pathology, ctDNA, radiology, etc.) be better harnessed and combined?
- ▶ Novel biomarker discovery and development
- ▶ Patient selection and precision medicine strategies
- ▶ Improved methods of early detection and early detection of relapse

OCTOBER

Translational insights: bridging the gap from preclinical R&D to the clinic

- ▶ What is going wrong between preclinical *in vitro*/*in vivo* settings and clinical *in vivo* settings?
- ▶ What model systems can predict patient response to investigational molecules in practice?
- ▶ How can current *in vitro* models be improved to better represent the complexity of the tumor, immune system, and surrounding tissue?
- ▶ What lessons can be drawn from previous negative outcomes from preclinical studies?

NOVEMBER

Addressing ongoing safety and toxicity issues

- ▶ Achieving the greatest benefit with the least toxicity
- ▶ How can we target tumor cells more accurately?
- ▶ Most solid tumor antigens are not restricted—are there subsets of targets that can be more specific?
- ▶ Mechanisms of anti-tumor activity and toxicity in I-O
- ▶ Does the field need to better manage toxicity with existing therapies, or find new targets and approaches?

DECEMBER

Tools and trends of tomorrow

- ▶ Exploring key enabling technology and platform innovation trends and advances for the year(s) to come
- ▶ Understanding the advancements being made in the solid tumor space—the progress so far and future trends

2024

EDITORIAL CALENDAR



Tools & Technologies channel focus

MARCH

Practical considerations for cutting edge tech

- ▶ How can tools such as AI be embedded into prospective ongoing clinical trials?
- ▶ As data science becomes increasingly important, how can we integrate/educate data scientists and cancer immunologists?
- ▶ Are tools like spatial omics practical and usable yet?

JULY

Turning data into knowledge

- ▶ How can emerging tools help to integrate and combine information from different sources and spanning different scales?

DECEMBER

Preclinical tools update

- ▶ Addressing lack of translatability from preclinical activity
- ▶ How can the field pick out the best candidates earlier and save crucial time and resources?
- ▶ Making models more applicable for safety and efficacy

Immuno-Oncology Insights provides you with fantastic opportunities to:

- ▶ **Educate your target market** about your company's expertise, capabilities and experience
- ▶ **Share your latest data** with organisations looking for partners and service providers in your field
- ▶ **Profile your executives and scientists** as thought-leaders and KOLs
- ▶ **Generate qualified leads** from across the global sector
- ▶ **Increase awareness** of your company's role in cell and gene therapy R&D and manufacture.

Contact Jamie Cox on +44 7734 562302 or jamie.cox@insights.bio to discuss thought leadership and lead generation opportunities